Stocks / AMEX / Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals, Inc.

Our Opinion

Rexahn Pharmaceuticals, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their pharmaceutical products and clinical research.

Evidence:
https://globenewswire.com/news-release/2016/10/10/878167/0/en/Rexahn-Pharmaceuticals-Presents-Preliminary-Efficacy-Data-from-Phase-Ib-IIa-Trial-of-RX-3117-in-Metastatic-Pancreatic-Cancer-and-Supinoxin-Phase-I-Trial-at-2016-European-Society-fo.html

“In preclinical animal models, where human cancer cells from breast, ovarian, melanoma, pancreas, or renal tumors were grafted into animals, treatment with Supinoxin resulted in a significant reduction in tumor growth.”

http://investors.rexahn.com/releasedetail.cfm?releaseid=949752

“By inhibiting Akt-1, Archexin has been shown to both inhibit the growth of renal cell carcinoma cell lines and exhibit a longer survival benefit in the human renal cell carcinoma animal xenograft model.”

Company Description

Rexahn Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. It dedicates to the discovery, development and commercialization of innovative treatments for cancer and other medical needs. The firm have three clinical stage oncology candidates: Archexin, RX-3117, and Supinoxin and a robust pipeline of preclinical compounds to treat multiple types of cancer. It has also developed proprietary drug discovery platform technologies in the areas of nano-medicines, 3D gold and times. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD. [Source: MarketWatch]